Takeda Issues U.S. Recall of NATPARA® (parathyroid hormone) for Injection Due to Potential for Rubber Particulates09/2019
On September 5, 2019, Takeda issued a recall of NATPARA® (parathyroid hormone) for Injection because of the potential for rubber particulates.
NATPARA is prescribed for some patients with hypoparathyroidism, a condition that can occur in patients after thyroid surgery due to loss or damage to the parathyroid glands. Hypoparathyroidism symptoms result from low levels of calcium in the blood.
Takeda has advised patients to immediately consult their healthcare providers to help ensure safe discontinuation of NATPARA treatment.
Takeda also reported that it is working closely with the United States Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible.